The intervention group: spironolactone at a fixed dose of 25 mg per day. The control group: placebo. Patients in both groups will be treated with the study medicine throughout 12 months and additionally follow the same therapeutic recommendations according to the Danish Society of Cardiology guidelines on treatment of AF.